Corticotropin-releasing hormone reduces pressure pain sensitivity in humans without involvement of β-endorphin(1-31), but does not reduce heat pain sensitivity

Neuroendocrinology

Volumn 82, Issue 3-4, 2005, Pages 185-197

  Matejec, Reginald ^a   Uhlich, Holger ^a   Hotz, Christina ^b   Mühling, Jörg ^a   Harbach, Heinz W ^a   Bödeker, Rolf H ^a   Hempelmann, Gunter ^a   Teschemacher, Hansjörg ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Clinical neuroendocrinology; Corticotropin releasing hormone; Endorphins; Neurokinin receptors; Pain; Proopiomelanocortin; Substance P; Thermosensitivity

Indexed keywords

ANALGESIC AGENT; BETA ENDORPHIN; BETA LIPOTROPIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CRH FERRING; MELANOCORTIN; NALOXON RATIOPHARM; NALOXONE; PLACEBO; PROOPIOMELANOCORTIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLUSHING; HEAT SENSITIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NOCICEPTION; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRESSURE SENSATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA;

ADRENOCORTICOTROPIC HORMONE; ADULT; BETA-ENDORPHIN; BETA-LIPOTROPIN; CORTICOTROPIN-RELEASING HORMONE; CROSS-SECTIONAL STUDIES; FEMALE; HEAT; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PRESSURE;

EID: 33646511078     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091980     Document Type: Article

References (51)

1. Amit Z, Galina ZH: Stress-induced analgesia: adaptive pain suppression. Physiol Rev 1986;66:1091-1120.
2. Hargreaves KM, Mueller GP, Dubner R, Goldstein D, Dionne RA: Corticotropin-releasing factor produces analgesia in humans and rats. Brain Res 1987;422:154-157.
3. Dunn AJ, Berridge CW: Physiological and behavioural responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71-100.
4. Ayesta FJ, Nikolarakis KE: Peripheral but not intracerebroventricular corticotropin-releasing hormone produces antinociception which is not opioid mediated. Brain Res 1989;503:219-224.
5. Hargreaves KM, Flores CM, Dionne RA, Mueller GP: The role of pituitary β-endorphin in mediating corticotropin-releasing factor induced antinociception. Am J Physiol 1990;258:235-242.
6. Wei ET, Kiang JG, Buchan P, Smith TW: Corticotropin-releasing factor inhibits neurogenic plasma extravasation in the rat paw. J Pharmacol Exp Ther 1986;238:783-787.
7. Kiang JG, Wei ET: Corticotropin-releasing factor inhibits thermal injury. J Pharmacol Exp Ther 1987;243:517-520.
8. Poree LR, Dickenson AH, Wei ET: Corticotropin-releasing factor inhibits the response of trigeminal neurons to noxious heat. Brain Res 1989;502:349-355.
9. Kita A, Imano K, Nakamura H: Involvement of corticotropin-releasing factor in the antinociception produced by interleukin-1 in mice. Eur J Pharmacol 1993;237:317-322.
10. Schäfer M, Mousa SA, Stein C: Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol 1997;323:1-10.
11. Hargreaves KM, Dionne RA, Mueller GP: Plasma β-endorphin-like immunoreactivity, pain and anxiety following administration of placebo in oral surgery patients. J Dent Res 1983;62:1170-1173.
12. Jarmukli NF, Ahn J, Iranmanesh A, Russell DC: Effect of raised plasma β-endorphin concentration on peripheral pain and angina thresholds in patients with stable angina. Heart 1999;82:204-209.
13. Matejec R, Harbach HW, Bödeker RH, Hempelmann G, Teschemacher H: Plasma levels of corticotroph-type POMC derivatives such as β-lipotropin, β-endorphin(1-31) or ACTH are correlated with severity of postoperative pain. Clin J Pain 2006;22(2):113-121.
14. Meyer RA, Davis KD, Cohen RH, Treede RD, Campbell JN: Mechanical insensitive afferents in cutaneous nerves of monkey. Brain Res 1991;561:252-261.
15. Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjork E, Handwerker H: Novel classes of responsive and unresponsive C nociceptors in human skin. J Neurosci 1995;15:333-341.
16. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996;383:819-823.
17. Matthes HWD, Smadja C, Valverde O, Vonesch JL, Foutz AS, Boudionot E, Denavit-Saubié M, Severini C, Negri L, Roques BP, Maldonado R, Kieffer BL: Activity of the δ-opioid receptor is partially reduced, whereas activity of the κ-receptor is maintained in mice lacking the μ-receptor. J Neurosci 1998;18:7285-7295.
18. Cogan R, Spinnato JA: Pain and discomfort thresholds in late pregnancy. Pain 1986;27:63-68.
19. Schürmeyer TH, Avgerinos PC, Gold PW, Gallucci WT, Tomai TP, Cutler GB, Loriaux DL, Chrousos GP: Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. J Clin Endocrinol Metab 1984;59:1103-1108.
20. Lautenbacher S, Roscher S, Kohl G, Vedder H, Krieg JC: Corticotropin-releasing hormone lacks analgesic properties: an experimental study in humans, using non-inflammatory pain. Pain 1999;83:1-7.
21. Goldfrank L, Weisman RS, Errick K, Lo MW: A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15:566-570.
22. Wiedemann K, Teschemacher H: Determination of β-endorphin and fragments thereof in human plasma using high-performance liquid chromatography and a multiple radioimmunoassay system. Pharmacol Res Commun 1986;3:142-149.
23. Harbach HW, Hell K, Gramsch C, Katz N, Hempelmann G, Teschemacher H: β-Endorphin(1-31) in the plasma of male volunteers undergoing physical exercise. Psychoneuroendocrinology 2000;25:551-562.
24. Matejec R, Schulz A, Harbach HW, Uhlich H, Hempelmann G, Teschemacher H: Effects of tourniquet-induced ischemia on the release of proopiomelanocortin derivatives determined in peripheral blood plasma. J Appl Physiol 2004;97:1040-1045.
25. Hunter WM, Greenwood FC: Preparation of iodine-131-labeled human growth hormone of high specific activity. Nature 1962;194:495-496.
26. Evans VR, Manning AB, Bernard LH, Chronwall BM, Millington WR: α-Melanocyte-stimulating hormone and N-acetyl-β-endorphin immunoreactivities are localized in the human pituitary but are not restricted to the zona intermedia. Endocrinology 1994;134:97-106.
27. Hollander M, Wolfe DA: Nonparametric Statistical Methods, ed 1. New York, Wiley, 1973, pp 33-64.
28. Castro MG, Morrison E: Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit Rev Neurobiol 1997;11:35-57.
29. Kieffer BL: Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 1995;15:615-635.
30. Matejec R, Ruwoldt R, Bödeker RH, Hempelmann G, Teschemacher H: Release of β-endorphin-immunoreactive material under perioperative conditions into blood or cerebrospinal fluid: significance for postoperative pain? Anesth Analg 2003;96:481-486.
31. Lacoumenta S, Yeo TH, Burrin JM, Hall GM: Beta-endorphin infusion fails to modulate the hormonal and metabolic response to surgery. Clin Endocrinol 1987;26:657-666.
32. Janson W, Stein C: Peripheral opioid analgesia. Curr Pharm Biotechnol 2003;4:270-274.
33. Schäfer M, Carter L, Stein C: Interleukin-1β and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 1994;91:4219-4223.
34. Treede RD, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992;38:397-421.
35. Djouhri L, Lawson SN: A β-fiber nociceptive primary afferent neurons: a review of incidence and properties in relation to other afferent A-fiber neurons in mammals. Brain Res Rev 2004;46:131-145.
36. Sang CN, Gracely RH, Max MB, Bennett GJ: Capsaicin-evoked mechanical allodynia and hyperalgesia cross nerve territories: evidence for a central mechanism. Anesthesiology 1996;85:491-496.
37. Voerman VF, van Egmond J, Crul BJP: Elevated detection thresholds for mechanical stimuli in chronic pain patients: support for a central mechanism. Arch Phys Med Rehabil 2000;81:430-435.
38. Kuraishi Y, Hirota N, Sato Y, Hino Y, Satoh M, Takagi H: Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res 1985;325:294-298.
39. Koppert W, Likar R, Geisslinger G, Zeck S, Schmelz M, Sittl R: Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth Analg 1999;88:117-122.
40. Lariviere WR, Melzack R: The role of corticotropin-releasing factor in pain and analgesia. Pain 2000;84:1-12.
41. Mousa SA, Schäfer M, Mitchell WM, Hassan AHS, Stein C: Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. Eur J Pharmacol 1996;311:221-231.
42. Martins JM, Kastin AJ, Banks WA: Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone. Neuroendocrinology 1996;63:338-348.
43. Kastin AJ, Akerstrom V: Differential interactions of urocortin/ corticotropin-releasing hormone peptides with the blood-brain barrier. Neuroendocrinology 2002;75:367-374.
44. Blanchi M, Sacerdote P, Locatelli L, Mantegazza P, Panerai AE: Corticotropin-releasing hormone, interleukin-1α, and tumor necrosis factor-α share characteristics of stress mediators. Brain Res 1991;546:139-142.
45. Bianchi M, Panerai AE: CRH and the noradrenergic system mediate the antinociceptive effect of central interleukin-1α in the rat. Brain Res Bull 1995;36:113-117.
46. Puder BA, Papka RE: Distribution and origin of corticotropin-releasing factor-immunoreactive axons in the female rat lumbosacral spinal cord. J Neurosci Res 2001;66:1217-1225.
47. Urban L, Thompson SW, Dray A: Modulation of spinal excitability: cooperation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci 1994;17:432-438.
48. Yoshihara S, Ricciardolo FLM, Geppetti P, Lindén A, Hara M, Chan B, Nadel JA: Corticotropin-releasing factor inhibits antigen-induced plasma extravasation in airways. Eur J Pharmacol 1995;280:113-118.
49. Liu J, Yu B, Neugebauer V, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, Gallagher JP: Corticotropin-releasing factor and urocortin I modulate excitatory glutamatergic synaptic transmission. Neuroscience 2004;24:4020-4029.
50. Pitcher GM, Henry JL: Nociceptive response to innocuous mechanical stimulation is mediated via myelinated afferents and NK-1 receptor activation in a rat model of neuropathic pain. Exp Neurol 2004;186:173-197.
51. Mansikka MD, Sheth RN, DeVries C, Lee H, Winchurch R, Raja SN: Nerve injury-induced mechanical but not thermal hyperalgesia is attenuated in neurokinin-1 receptor knockout mice. Exp Neurol 2000;162:343-349.